Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

× No keyword cloud information.

13 in total

1. Personalized ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.

Authors: Michela Del Prete; François-Alexandre Buteau; Frédéric Arsenault; Nassim Saighi; Louis-Olivier Bouchard; Alexis Beaulieu; Jean-Mathieu Beauregard
Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-30 Impact factor: 9.236

Review 2. Correlation of dose with toxicity and tumour response to ⁹⁰Y- and ¹⁷⁷Lu-PRRT provides the basis for optimization through individualized treatment planning.

Authors: Marta Cremonesi; Mahila Esmeralda Ferrari; Lisa Bodei; Carlo Chiesa; Anna Sarnelli; Cristina Garibaldi; Massimiliano Pacilio; Lidia Strigari; Paul Eugene Summers; Roberto Orecchia; Chiara Maria Grana; Francesca Botta
Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-21 Impact factor: 9.236

Review 3. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.

Authors: Shagufta Shaheen; Farshad Moradi; Gerardo Gamino; Pamela L Kunz
Journal: Curr Treat Options Oncol Date: 2020-03-14

4. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.

Authors: M Chantadisai; H R Kulkarni; R P Baum
Journal: Eur J Nucl Med Mol Imaging Date: 2020-11-27 Impact factor: 9.236

5. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy.

Authors: Thomas A Hope; Lisa Bodei; Jennifer A Chan; Ghassan El-Haddad; Nicholas Fidelman; Pamela L Kunz; Josh Mailman; Yusuf Menda; David C Metz; Erik S Mittra; Daniel A Pryma; Diane L Reidy-Lagunes; Simron Singh; Jonathan R Strosberg
Journal: J Nucl Med Date: 2020-02 Impact factor: 11.082

6. Prospective observational study of ¹⁷⁷Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.

Authors: Ulrike Garske-Román; Mattias Sandström; Katarzyna Fröss Baron; Lars Lundin; Per Hellman; Staffan Welin; Silvia Johansson; Tanweera Khan; Hans Lundqvist; Barbro Eriksson; Anders Sundin; Dan Granberg
Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-01 Impact factor: 9.236

Review 7. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights.

Authors: Jason S Starr; Mohamad Bassam Sonbol; Timothy J Hobday; Akash Sharma; Ayse Tuba Kendi; Thorvardur R Halfdanarson
Journal: Onco Targets Ther Date: 2020-04-28 Impact factor: 4.147

Review 8. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies.

Authors: Niloefar Ahmadi Bidakhvidi; Karolien Goffin; Jeroen Dekervel; Kristof Baete; Kristiaan Nackaerts; Paul Clement; Eric Van Cutsem; Chris Verslype; Christophe M Deroose
Journal: Cancers (Basel) Date: 2021-12-28 Impact factor: 6.639

9. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog ¹⁷⁷Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors.

Authors: Qingxing Liu; Yuejuan Cheng; Jie Zang; Huimin Sui; Hao Wang; Orit Jacobson; Zhaohui Zhu; Xiaoyuan Chen
Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-12 Impact factor: 9.236

10. Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.

Authors: Selin Kucukyurt; Yeliz Yagiz Ozogul; Abdulkadir Ercaliskan; Levent Kabasakal; Ahmet Emre Eskazan
Journal: Cancer Rep (Hoboken) Date: 2020-09-07

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

1. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.

Review 2. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.